cancer risk with semaglutide GLP-1s appear to cut risk. Researchers are asking why and how : NPR Research Reveals Potential Risks of

Introduction# Ribupatide (HRS9531/KAI-9531, Hengrui Pharma/Kailera Therapeutics) and tirzepatide (Eli Lilly) share the same dual GLP-1/GIP receptor agonist mechanism, making this a direct mechanistic comparison

Panel b : The proportion of participants achieving total body fat mass reduction thresholds at Week 72 is calculated based on logistic regression with mixed model repeated measures for missing data imputation using an efficacy estimand

It is more likely if you take too much of it

By reducing insulin resistance, semaglutide may help the ovaries function more regularly, which could improve menstrual regularity for some women